Previous 10 | Next 10 |
home / stock / bhc:cc / bhc:cc news
LAVAL, QC / ACCESSWIRE / March 6, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals, today announced that it is supporting a Phase 2 investigator-initiated study (IIS) of RELISTOR® (methylnaltrexone bromide: MNTX) in patients wi...
Salix Pharmaceuticals Releases Findings from First Colonoscopy Awareness Survey LAVAL, QC / ACCESSWIRE / March 5, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals, today announced findings from its first colonoscopy awareness an...
LAVAL, QC / ACCESSWIRE / March 1, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that members of company management will participate at the Cowen Annual Health Care Conference in Boston on March 5, 2024. The Bausch Health team will be hosting a fireside chat at 12:50 p.m...
2024-02-29 16:50:00 ET The last few years saw a surge in healthcare companies entering the market. The pandemic led to many opportunities and many failures. So, where can investors go to invest in what really should be a stable area of investment? After all, we’re always going to...
2024-02-24 09:09:44 ET Summary Bausch Health is burdened by a heavy debt load of over $20 billion, impacting its equity valuation. The resolution to the leverage issues lies in divesting Bausch + Lomb Corp shares, which could bring in much-needed cash to reduce debt. The dives...
2024-02-22 12:30:26 ET Bausch Health Companies Inc. (BHC) Q4 2023 Earnings Conference Call February 22, 2024 8:00 am ET Company Participants Thomas Appio - Chief Executive Officer John Barresi - Senior Vice President, Chief Financial Officer (interim) Maria Likur...
2024-02-22 08:58:29 ET More on Bausch Health Companies Bausch Health: $20bn Debt Is A Mighty Elephant In The Room Emergent surges 66% as it brings in Bausch + Lomb vet Papa as CEO Bausch Health Companies Q4 2023 Earnings Preview Seeking Alpha’s Quant R...
Fourth-Quarter revenues of $2.41 billion, up 10% on a Reported basis and up 4% on an Organic 1 basis Full-Year revenues of $8.76 billion, up 8% on a Reported basis and 7% on an Organic 1 basis Full-Year revenue growth in Salix, International, Solta and Bausch + Lomb segments on both...
Morguard Corporation (MRC:CA) is expected to report for Q4 2023 Maple Leaf Foods Inc. (MFI:CA) is expected to report for quarter end 2023-12-31 EQB Inc. (EQB:CA) is expected to report $3.63 for Q4 2023 Lundin Gold Inc. (LUG:CA) is expected to report $0.2 for Q4 2023 Vista Gold Cor...
2024-02-21 13:11:49 ET More on Emergent Biosolutions Emergent BioSolutions: Q3 Numbers Leave Work To Be Done Emergent BioSolutions extends shelf life of Narcan to 4 years Emergent BioSolutions wins $235.8M DoD contract Seeking Alpha’s Quant Rating on E...
News, Short Squeeze, Breakout and More Instantly...
Bausch Health Companies Inc. Company Name:
BHC:CC Stock Symbol:
TSXC Market:
Bausch Health Companies Inc. Website:
LAVAL, QC / ACCESSWIRE / July 11, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release second quarter 2024 financial results on Thursday, August 1, 2024. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EST to discuss the results and provide a business...
The S&P 500 rose to a new high on Friday, putting the broad-market index on track for yet another weekly gain during the holiday-shortened trading week. The tech-heavy NASDAQ Composite also hit a new high. The Dow Jones Industrials climbed 67.87 points to end Friday at 39,375.87. The ...
2024-06-24 10:24:32 ET Investors are on the precipice of greatness these days. While we aren’t in a bull market yet, we are so close . And that makes it the perfect time to get in on some amazing stocks due to recover and rebound with massive returns. In fact, one might call ...